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Abstract
Background: Breast cancer survivors are at risk of developing breast cancer-related lymphedema (BCRL) after
surgical treatment, which may have a negative effect on quality of life. The purpose of this study was to investigate
the clinical role of bioelectrical impedance analysis (BIA) and the relationship between the development of BCRL in
breast cancer survivors who have undergone axillary surgery.
Methods: A total of 228 patients with breast cancer were enrolled in the study between May 2016 and January
2017. BCRL was assessed by measuring the circumference of both arms at 15 cm below the acromion process and
the olecranon process. Patients were classified as BCRL (n = 22) and non-BCRL (n = 206) based on the difference of
the arm circumference of 2 cm. Data including lymphedema, anthropometry, BIA measurements, food frequency
questionnaire, type of surgery, total number of dissected lymph nodes, and post-operative treatment were collected.
Results: Of the breast cancer survivors, 10.4% had BCRL by the definition. The BCRL group contained 22 patients, while
the non-BCRL group contained 206 patients. Compared to the non-BCRL group, the BCRL group had a higher body
mass index, a larger percentage of ideal body weight, more dissected lymph nodes, and higher single frequency BIA
(SFBIA) ratio (P = 0.027, P = 0.031, P < 0.001, and P < 0.001, respectively). The SFBIA ratio provided 63.64% sensitivity and
95.15% specificity in estimating the risk of BCRL.
Conclusion: Our data provides evidence to support that the use of SFBIA ratio can serve as an alternative method to
monitor and/or diagnose BCRL.
Trial registration: This trial was retrospectively registered at Clinicaltrials.gov identifier (NCT03391206) on the 5 January
2018.
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Background
Lymphedema can be clinically diagnosed based on the
swelling of limbs. However, definitive diagnosis of
lymphedema is difficult, because most would suggest
that lymphatic dysfunction imaged by lymphoscintigra-
phy or indocyanine green lymphography is required.
The clinical diagnosis of lymphedema includes the ob-
servation that the bilateral difference in limb circumfer-
ence is 2 cm or more [1], the difference of pre and post
operation in volume of the limb is more than 200 ml
[2], or the bilateral difference in volume of the limb
change is 10% [3]. Because of differences in diagnostic
criteria in these measurement methods, the definitive
diagnosis is difficult. In addition, ultrasound, computed
tomography, and magnetic resonance imaging are used
to diagnose lymphedema. The ultrasound can measure
volumetric and structural changes in the dermis,
subcutaneous layer, and muscle, but information on the
truncal anatomy of the lymphatic system can not be
confirmed [4]. The computed tomography can detect
thickening of the skin and subcutaneous compartment,
and thickened perimuscular aponeurosis [4]. The mag-
netic resonance imaging can distinguish lymphedema,
lipedema, and phlebedema, and can confirm the cir-
cumferential measurement edema, thickened dermis,
and increased subcutaneous compartment [4, 5].
The arm circumference measurement is a commonly
utilized clinical diagnosis method [6]. The circumference
of both arms at 15 cm below the acromion process and
the olecranon process is measured, and the circumference
values of the affected arm and unaffected arm are com-
pared [6, 7]. However, with this method there is no stan-
dardized reference point and low sensitivity. The lack of
evidence-based diagnostic criteria to define lymphedema
has presented tremendous challenges in terms of diagno-
sis. Therefore, defining criteria for the early detection and
treatment of lymphedema is important [8].
Recently, several researchers have used bioelectrical im-
pedance analysis (BIA) to diagnose lymphedema [9–14].
This method is highly sensitive, can be used as a basis to
establish standardized criteria, and can be used to measure
extracellular space [9, 15, 16]. Bioelectrical impedance
predicts body composition using differences in electric
conductivity upon sending a minute current through the
human body [17, 18]. In several studies, the single
frequency bioelectrical impedance analysis (SFBIA) of the
two arms obtained using bioelectrical impedance mea-
surements was expressed as the ratio of the values of the
operated and non-operated arms [10, 19]. However, this
method has not been validated as a diagnostic tool. It is
therefore necessary to study this method further to estab-
lish it as an efficient diagnostic means.
The purpose of this study is to determine diagnostic
accuracy of bioelectrical impedance as a diagnostic
method based on the presence of lymphedema com-
pared with circumference measurements. In addition,
the aim is to identify risk factors to help prevent lymph-
edema for breast cancer survivors.
Methods
Study design and subjects
This prospective study was conducted at Severance Hos-
pital in Korea from May 2016 to January 2017 and in-
volved female unilateral breast cancer survivors aged 20
or older who underwent surgery at least six months prior
to selection. Patients with bilateral breast cancer, male
breast cancer, recurrent breast cancer, previous ipsilateral
axillary surgery, and previous radiotherapy were excluded.
This study was approved by the Institutional Review
Board of Severance Hospital (IRB Number: 4–2016-0149).
All patients participated voluntarily in the study and pro-
vided written informed consent. All subjects underwent
BIA, body measurements and semi-quantitative food fre-
quency questionnaire for the Korean Genome Epidemio-
logic Study [20].
A total of 250 patients were recruited. A total of 228 pa-
tients were finally enrolled in the study. (Clinicaltrials.gov
identifier: NCT03391206). Of the patients who were ex-
cluded, 10 had bilateral breast cancer, 10 had poor medical
records, and two did not have bioelectrical impedance
measured (Fig. 1). The presence or absence of lymphedema
was assessed in 228 patients based on circumference mea-
surements [6]. Arm circumference measurements were ex-
amined using a method that was described in the previous
study definition [21]. The circumference of both arms at
15 cm below the acromion and the olecranon process was
measured, and the measured values of the affected and
unaffected arm were compared. Patients were classified as
BCRL group (n = 22) with a difference more than or equal
to 2 cm and non-BCRL group (n = 206) with a difference
less than 2 cm.
Anthropometric parameter and body composition
measurements
Body height was measured using an automatic extension
meter. Body composition analysis was performed with an
Inbody 720 composition analyzer (Biospace, Seoul, South
Korea). Before assessment, participants were instructed to
avoid excessive fluid intake, alcohol ingestion and heavy
physical activity. Subjects were asked to remove anything
metal and to stand barefoot on the metal footpads while
loosely holding the handgrips. The results were automatic-
ally input into the system. Body weight, fat mass, body
mass index (BMI), the waist-hip ratio (WHR), percent of
ideal body weight (PIBW), extracellular water (ECW),
total body water (TBW), and SFBIA were measured using
BIA. SFBIA values were noted for both upper extremities
at 1 kHz and 5 kHz. The SFBIA ratio was calculated as the
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ratio of the values of the affected to unaffected arms [14].
The SFBIA ratio was used to assess lymphedema.
BMI, PIBW, and SFBIA ratio were calculated as follows;
BMI
BMI = body weight in kilograms / (height in meters)2.
PIBW
PIBW = actual weight / ideal body weight*× 100.
*ideal body weight = (height in meters)2xideal BMI#.
#ideal BMI = female; 21 kg/m2, male; 20 kg/m2.
SFBIA ratio
SFBIA ratio = unaffected SFBIA / affected SFBIA.
Medical record collection
Clinicopathological information was obtained from the
medical records of the participating women. Clinicopatho-
logical variables included surgery type (sentinel lymph node
biopsy (SLNB) or axillary lymph node dissection (ALND)),
number of dissected lymph nodes, and postoperative ther-
apy such as chemotherapy, radiotherapy, hormone therapy,
and target therapy.
Statistical analysis
The variables used in this study were anthropometric
values, the SFBIA value, the intake of nutrients, activity
level, healthy functional foods, surgical methods, the num-
ber of removed lymph nodes, and treatment methods. The
results are described as mean and standard deviation. The
relationship between variables in the non-BCRL and BCRL
groups was analyzed. The chi-squared test or Fishers exact
test and independent sample t-test or Mann-Whitney U
test were used for the analyses. The reported p-values are
two-sided and were considered statistically significant at
0.05 or less. All data analyses were performed using IBM




Table 1 details the general characteristics of the study pa-
tients, who were classified according to axillary surgery
type (SLNB or ALND) and the presence or absence of
lymphedema (Non-BCRL or BCRL). No significant differ-
ences between the non-BCRL group and BCRL group
were found in terms of age or physical activity level. The
Fig. 1 Flowchart illustrating the classification of the study participants in breast cancer survivors
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lymphedema of the operated site was significantly higher
in the right side than in the left side. The number of
lymph nodes removed was significantly higher in the
BCRL than in the non-BCRL, but this difference was not
observed when the subjects were divided according to
surgery type (SLNB or ALND). The mean value of the
acromion circumference difference was 2.69 ± 1.70 cm in
the BCRL group. The arm circumference difference was
larger in the lymphedema group with ALND than in the
group with SLNB.
Anthropometry and bioelectrical impedance data
The anthropometric data including body weight, fat mass,
BMI, body fat percentage (BFP), WHR, PIBW, ECW/
TBW, and SFBIA ratio were compared between the non-
BCRL and BCRL groups for each surgery type (Table 2).
BMI was significantly higher in the BCRL group (P =
0.027). Obesity-related factors including body weight, fat
mass, BFP, PIBW, and BMI were significantly higher in the
BCRL group than in the non-BCRL group for SLNB
patients, while there were no significant differences among
the ALND patients.
Diagnosis of lymphedema using SFBIA ratio
Table 3 summarizes SFBIA ratios calculated from the ratio
of the values of the operated and non-operated arms. The
SFBIA values of the bioelectrical impedance were mea-
sured at 1 kHz and 5 kHz. The 1 kHz SFBIA ratio of the
BCRL and non-BCRL groups was 1.145 ± 0.234 and
0.996 ± 0.039 (p < 0.001), respectively. The 5 kHz SFBIA
ratio was significantly higher in the BCRL group than in
the non-BCRL group (p < 0.001). Regarding the SFBIA
Table 1 General characteristics of the study population
SLNB (n = 148) ALND (n = 80) Total (n = 228)
Non-BCRL BCRL P valuea Non-BCRL BCRL P valueb Non-BCRL BCRL P valueb
(n = 142) (n = 6) (n = 64) (n = 16) (n = 206) (n = 22)
Age (years) 53.2 ± 10.0 56.7 ± 15.0 0.556 59.1 ± 10.4 58.7 ± 6.7 0.124 52.8 ± 9.7 56.3 ± 12.0 0.121
Operated site
Left 68 (47.9) 1 (16.7) 0.133 33 (51.6) 4 (25.0) 0.057 101 (49.0) 5 (22.7) 0.019
Right 74 (52.1) 5 (83.3) 31 (48.4) 12 (75.0) 105 (51.0) 17 (77.3)
No. of dissected lymph nodes 4.2 ± 2.3 5.0 ± 2.5 0.507 15.7 ± 7.5 19.7 ± 7.4 0.057 7.7 ± 7.0 15.7 ± 9.2 0.001
Therapyc
Chemotherapy 53 4 34 9 87 13
Radiotherapy 88 4 47 15 135 19
Hormonal therapy 113 4 44 12 157 16
Target therapy 8 1 11 3 19 4
Missing data 1 0 2 0 3 0
Circumference differenced
Acromion 0.57 ± 0.52 2.37 ± 0.59 0.000 0.71 ± 0.64 2.81 ± 1.97 0.001 0.58 ± 0.49 2.69 ± 1.70 0.000
Olecranon 0.58 ± 0.50 1.52 ± 1.02 0.010 0.54 ± 0.41 2.09 ± 2.10 0.010 0.55 ± 0.46 1.93 ± 1.867 0.002
Physical activity
Inactivee 1 (0.7) 0 (0.0) 0.631 0 (0.0) 0 (0.0) 0.204 1 (0.5) 0 (0.0) 0.210
Sedentaryf 23 (16.2) 1 (16.7) 11 (17.2) 5 (31.3) 34 (16.5) 6 (27.3)
Activeg 88 (62.0) 5 (83.3) 38 (59.4) 10 (62.5) 126 (61.2) 15 (68.2)
Very activeh 30 (21.1) 0 (0.0) 15 (23.4) 1 (6.3) 45 (21.8) 1 (4.5)
Health supplement foodc
Vitamin & mineral agent 76 4 30 6 106 10
Other dietary supplement 2 39 21 7 60 9
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL Breast cancer-related lymphedema
Values are mean ± standard deviation or N (percentage)
aDifferences between BCRL and Non-BCRL were tested by the Mann-Whitney U test and the Pearson’s chi-squared test
bDifferences between BCRL and Non-BCRL were tested by the Student’s t-test and the Pearson’s chi-squared test
cOccasionally, one or more treatments were given to one person
dCircumference difference were calculated by the equation affected length minus the unaffected length
eInactive: Limited physical activity (eg. inpatient)
fSedentary: Most of the time is spent sitting in a static activity
gActive: Most of the time spent sitting, but lifestyle also includes standing work, commuting, buying things, housework, light exercise
hVery active: Strenuous work or highly active leisure
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ratio, a significant difference was observed between the
non-BCRL and BCRL groups for ALND patients, but there
was a tendency without significance for SLNB patients.
Receiver operating characteristic curve (ROC) analyses
were performed in order to evaluate diagnostic ability of
SFBIA ratio using the1 kHz and 5 kHz SFBIA ratios.
Figure 2 shows the ROC curve in 1 kHz and 5 kHz. Our
SFBIA ratio cut-off value are 1.049 and 1.047, respect-
ively. Area under the curve of 5 kHz SFBIA ratio was
higher than that of 1 kHz (5 kHz; 0.77, 1 kHz; 0.74).
The 5 kHz SFBIA ratio showed better performance as a
diagnostic tool compared to 1 kHz SFBIA ratio with an
area under the curve of 0.77 (95% CI: 0.63–0.90). The
5 kHz SFBIA ratio values were used as criteria for
determining the occurrence of lymphedema in each
patient. The analysis of diagnostic accuracy of the 5
kHz SFBIA showed specificity of 95.15%, sensitivity of
63.64%, positive predictive value of 58.33%, and nega-
tive predictive value of 96.08%.
Discussion
Early prevention and detection of postoperative lymph-
edema complications in breast cancer patients is important
for quality of life. Our data provided evidence to support
the use of the SFBIA ratio by BIA in lymphedema in breast
cancer survivors. In addition, right axillary surgery was sug-
gested to be a risk factor associated with lymphedema.
Lymphedema was more common in patients with the right
axillary procedure than those with the left. This may be
due to the fact that right handed people are more common
and have more axillary activity on the right side. Addition-
ally, the number of dissected lymph nodes [22–25], obesity
[23, 24, 26, 27], and surgery type [22, 24, 25] were risk
factors for lymphedema. It was concordant with previous
study [22–27].
In this study, BCRL was determined based on more
than a 2 cm difference in the circumference, as mea-
sured 15 cm below the olecranon, or acromion process,
of the arm not affected by the operation relative to the
Table 2 Analysis of BCRL and non- BCRL values through bioelectrical impedance analysis
SLNB ALND Total
(n = 148) (n = 80) (n = 228)
Non-BCRL BCRL P valuea Non-BCRL BCRL P valueb Non-BCRL BCRL P valueb
(n = 142) (n = 6) (n = 64) (n = 16) (n = 206) (n = 22)
BW (kg) 59.4 ± 10.6 72.4 ± 12.0 0.009 59.1 ± 10.4 58.7 ± 6.7 0.878 59.3 ± 10.5 62.4 ± 10.2 0.183
FFM (kg) 39.3 ± 4.5 43.8 ± 4.4 0.052 39.3 ± 4.7 38.4 ± 4.2 0.494 40.3 ± 14.6 39.9 ± 4.8 0.904
FM (kg) 20.1 ± 7.7 28.6 ± 8.0 0.016 19.8 ± 7.5 20.3 ± 4.8 0.816 20.0 ± 7.6 22.5 ± 6.8 0.131
BMI (kg/m2)c 23.8 ± 4.2 28.4 ± 4.5 0.011 23.6 ± 4.0 24.7 ± 2.7 0.275 23.7 ± 4.1 25.7 ± 3.6 0.027
BFP (%) 32.8 ± 7.2 38.8 ± 5.1 0.034 32.8 ± 6.5 34.2 ± 5.6 0.421 32.8 ± 7.0 35.5 ± 5.8 0.084
WHR 0.87 ± 0.06 0.89 ± 0.05 0.180 0.86 ± 0.05 0.89 ± 0.05 0.180 0.87 ± 0.06 0.89 ± 0.05 0.088
PIBWd 112.6 ± 20.0 134.7 ± 21.8 0.012 111.6 ± 19.0 116.9 ± 13.1 0.296 112.3 ± 19.6 121.7 ± 17.3 0.031
ECW/TBW 0.39 ± 0.01 0.39 ± 0.01 0.312 0.39 ± 0.01 0.39 ± 0.01 0.168 0.39 ± 0.01 0.39 ± 0.01 0.068
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL breast cancer-related
lymphedema, BW body weight, FFM fat free mass, FM fat mass, BMI body mass index, BFP body fat percentage, WHR waist-Hip ratio, PIBW percent of ideal body
weight, ECW/TBW extracellular water/total body water
Values are mean ± standard deviation
aP values of differences between means were calculated using the Mann-Whitney U test
bP values of differences between means were calculated using an independent sample t-test
cBody mass index(BMI) was calculated body weight in kilograms/(height in meters)2
dPercent of ideal body weight(PIBW) was determined by the equation actual weight (kg)/ideal body weight (kg) × 100
Table 3 SFBIA ratioa of breast cancer survivors according to lymphedema
SLNB ALND Total
(n = 148) (n = 80) (n = 228)
Non-BCRL BCRL P valueb Non-BCRL BCRL P valuec Non-BCRL BCRL P valuec
(n = 142) (n = 6) (n = 64) (n = 16) (n = 206) (n = 22)
1 kHz 0.991 ± 0.039 1.013 ± 0.045 0.183 1.006 ± 0.036 1.194 ± 0.257 < 0.001 0.996 ± 0.039 1.145 ± 0.234 < 0.001
5 kHz 0.990 ± 0.036 1.016 ± 0.037 0.075 1.004 ± 0.037 1.177 ± 0.250 < 0.001 0.994 ± 0.037 1.133 ± 0.225 < 0.001
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL breast cancer-related
lymphedema, SFBIA ratio single-frequency bioelectrical impedance analysis ratio
Values are mean ± standard deviation
aSingle-frequency bioelectrical impedance analysis(SFBIA) ratio of the affected to unaffected side were calculated
bP values of differences between means were calculated using the Mann-Whitney U test
cP values of differences between means were calculated using an independent sample t-test
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circumference of the arm on the same side as the oper-
ation [7, 28, 29]. Limitations include potential errors in
the measurements and the fact that diagnosis is not
possible until clinical symptoms are seen. More precise
techniques including ultrasound, computed tomography,
magnetic resonance imaging, lymphoscintigraphy and
other volumetric measurement can enhance the diagno-
sis of lymphedema. Further studies that evaluate the
comparison these techniques and BIA are needed.
BIA is designed to measure edema as an extremely small
electrical current passes through extracellular fluid [9].
This technique distinguishes extracellular fluid from total
limb volume [9, 30]. In the presence of lymphedema, the
SFBIA ratio [10] is related to the accumulation of extracel-
lular fluid [31]. Our results show that the SFBIA ratio is
larger at 5 kHz than at 1 kHz. BIA had good performance
in terms of specificity (95.15%) and negative predictive
value (96.08%). A diagnostic tool with a high specificity is
more useful for ‘judging’ a disease when a person is posi-
tive and the negative predictive value can be used that the
probability of not having disease given a negative diagnosis
[32]. These values indicate that BIA can be used as a
method of monitoring and diagnosing lymphedema.
Previous studies have reported that early surveillance for
risk of lymphedema using bioimpedance spectroscopy
with early intervention with compression garments can
reduce the incidence of more advanced lymphedema [11,
12]. Our cut-off value of the SFBIA ratio for diagnosing
lymphedema should be validated in further studies. The
usefulness of early detection through the SFBIA ratio is
necessary to be evaluated as well.
Well-known risk factors for lymphedema include the
surgery type [22, 24, 25] and the number of dissected
lymph nodes [22–25]. Similarly, our study also demon-
strated that the higher the number of lymph nodes
removed in the ALND subjects, the higher the incidence of
lymphedema. However, these were not observed for the
SLNB because the number of lymph nodes removed is too
small to affect the risk of lymphedema in these subjects.
Overall, on average our SLNB subjects had less than 5
lymph nodes removed whereas the ALND had 16 to 20
lymph nodes removed. Thus, surgery type associated with
high lymph node removal is likely to increase the risk of
lymphedema as reported previously [22–25].
Obesity-related indicators in breast cancer patients in-
crease the risk of developing lymphedema complications
[26, 33, 34]. Our data investigated the relationship
between the incidence of lymphedema and the variables
related to anthropometric measurements and type of sur-
gery. The BMI and PIBW of the subjects were significantly
higher in the presence of lymphedema. In particular, body
fat percentage, BMI, and PIBW were significantly different
in patients who underwent SLNB. These findings suggest
that the occurrence of lymphedema is associated with
obesity and that patients who undergo SLNB procedures
should pay attention to maintaining normal weight. There
was no significant difference of obesity-related indicators
between BCRL and non-BCRL in the patients with ALND.
Our results were different from the studies conducted on
Westerners. The association between BMI and lymph-
edema volume in patients with ALND was observed [35,
36]. The difference between ours and previous studies
Fig. 2 ROC curve of the 1 kHz and 5 kHz SFBIA ratio value. After the breast cancer surgery, the 1 kHz and 5 kHz SFBIA ratio of the survivors
showed the good test performance to detect lymphedema with an area under the curve of 0.74 (95% CI: 0.59–0.89) and 0.77 (95% CI: 0.63–0.90),
respectively. The 1 kHz and 5 kHz SFBIA ratio were effective predictors of post–BCRL(p = 0.000, p = 0.000)
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may be due to difference of study population, a race, cul-
ture, lifestyle, and dietary differences between Westerners
and Asians. Further research is needed to understand the
factors behind these differences.
The lymphedema of our subjects was confirmed by the
difference in limb circumference of 2 cm of both sides.
This confirmed the lymphedema of the arm, but not the
lymphedema that appeared at other sites. Therefore, the
diagnosis of more detailed lymphedema will establish an
accurate standard of the SFBIA ratio. Nevertheless, our
study confirmed the cut-off value of the SFBIA ratio for
the determination of lymphedema through 228 subjects
and confirmed the sensitivity and specificity. Our findings
have shown the possibility of SFBIA ratio as a useful tool
for the diagnosis and management of lymphedema in
breast cancer survivors. In addition, we found that there
was a significant correlation between lymphedema and
obesity in patients who underwent SLNB, but not in
patients who underwent ALND.
Conclusion
The SFBIA ratio obtained using BIA can be an alternative
method for monitoring and/or diagnosing BCRL. The BIA
had a sensitivity of 63.64% and a specificity of 95.15% in
predicting BCRL. In addition, number of dissected lymph
nodes, operation site, surgery type, obesity, and the SFBIA
ratio are significantly associated with the occurrence of
lymphedema.
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